Insulin Glargine News and Research

RSS

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults

A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.

26 Jun 2012

Insulin more effective add-on than sitagliptin in glucose control

Insulin seems to be a more effective add-on regimen than sitagliptin in patients with diabetes inadequately controlled by metformin monotherapy, show study findings.

15 Jun 2012

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

Long-term insulin use does not increase risk of heart disease in people with diabetes

Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

13 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

23 Mar 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies.

9 Nov 2011

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes.

From Novo Nordisk 15 Sep 2011

Lantus initiation may help limit weight gain in type 2 diabetes patients

Sanofi announced today data that demonstrates that initiating Lantus® (insulin glargine [rDNA origin] injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics and dietary changes.

12 Sep 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Novo Nordisk has completed a pre-specified meta-analysis based on the Degludec phase 3a trial programme. The meta-analysis confirmed that Degludec is associated with a lower risk of hypoglycaemia compared to insulin glargine, both on the total number of confirmed hypoglycaemic events, and on the number of confirmed nocturnal hypoglycaemic events. Both findings are statistically significant.

From Novo Nordisk 28 Apr 2011

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Boehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

12 Jan 2011

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Eli Lilly and Company and Boehringer Ingelheim today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

11 Jan 2011

Insulin Glargine News and Research

Insulin glargine retards progression of atherosclerosis in high-risk people

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults

Insulin more effective add-on than sitagliptin in glucose control

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Long-term insulin use does not increase risk of heart disease in people with diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

European Commission grants marketing authorization for use of BYETTA with basal insulin

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin outlines key strategic priorities for 2012

Amylin and Lilly terminate exenatide alliance, resolve litigation

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Lantus initiation may help limit weight gain in type 2 diabetes patients

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News